This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported by Novartis Pharmaceuticals Corporation, US.
Reference
Mannino DM, et al. Economic Burden of Chronic Obstructive Pulmonary Disease by Presence of Comorbidities. Chest : 12 Feb 2015. Available from: URL: http://doi.org/10.1378/chest.14-2434
Rights and permissions
About this article
Cite this article
CKD key driver of healthcare costs in COPD. PharmacoEcon Outcomes News 722, 8 (2015). https://doi.org/10.1007/s40274-015-1914-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-1914-3